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Abstract
Background: Little current information is available for prevalence of vertically-transmitted
infections among the Afghan population. The purpose of this study is to determine prevalence and
correlates of human immunodeficiency virus (HIV), syphilis, and hepatitis B and C infection among
obstetric patients and model hepatitis B vaccination approaches in Kabul, Afghanistan.
Methods: This cross-sectional study was conducted at three government maternity hospitals in
Kabul, Afghanistan from June through September, 2006. Consecutively-enrolled participants
completed an interviewer-administered survey and whole blood rapid testing with serum
confirmation for antibodies to HIV, T. pallidum, and HCV, and HBsAg. Descriptive data and
prevalence of infection were calculated, with logistic regression used to identify correlates of HBV
infection. Modeling was performed to determine impact of current and birth dose vaccination
strategies on HBV morbidity and mortality.
Results: Among 4452 women, prevalence of HBsAg was 1.53% (95% CI: 1.18 – 1.94) and anti-HCV
was 0.31% (95% CI: 0.17 – 0.53). No cases of HIV or syphilis were detected. In univariate analysis,
HBsAg was associated with husband's level of education (OR = 1.13, 95% CI: 1.01 – 1.26). Modeling
indicated that introduction of birth dose vaccination would not significantly reduce hepatitis-related
morbidity or mortality for the measured HBsAg prevalence.
Conclusion: Intrapartum whole blood rapid testing for HIV, syphilis, HBV, and HCV was
acceptable to patients in Afghanistan. Though HBsAg prevalence is relatively low, periodic
assessments should be performed to determine birth dose vaccination recommendations for this
setting.
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Testing for human immunodeficiency virus (HIV), syphi-
lis, and hepatitis B surface antigen (HBsAg) in pregnancy
and labor is medically indicated to prevent vertical trans-
mission. Prevalence of these infections among the antena-
tal population may be a reliable indicator of general
population prevalence and determinant of vaccination
policy [1-3]. The intrapartum period may be the only clin-
ical access point for the antenatal population in limited
resource settings. Successful interventions to prevent ver-
tical transmission linked to intrapartum rapid testing have
been demonstrated in a variety of limited resource settings
[4,5]. One such intervention is birth dose hepatitis B vac-
cine. Recommendations for birth dose vaccination are
determined by antenatal prevalence of hepatitis B e anti-
gen (HBeAg) and to some degree by HBsAg in settings
where HBeAg prevalence is unknown [6]. Risk of vertical
transmission should not be underestimated in settings
where HBeAg is relatively low or assumed to be low;
Chauvin et al. indicate that even in settings where HBeAg
prevalence among mothers is relatively low (< 20%), the
number of chronic carriers resulting from lack of birth
dose vaccination exceeds 500/100,000, the threshold for
instituting other neonatal immunization programs, such
as poliomyelitis [7]. In many settings, resources do not
exist to assess HBeAg prevalence so vaccination policy
may be made on HBsAg prevalence alone.
Afghanistan has an evolving health infrastructure and
many barriers remain to accessible care, including ongo-
ing conflict and a shortage of trained providers. Blood
donor data is the sole published source of population-
based prevalence data. From March through December
2006, the Central Blood Banks in Afghanistan reported
prevalence of transfusion-associated infections based on
single screening test protocol [8]. For Kabul province, low
prevalence of HIV antibody (0.0006%), syphilis-sugges-
tive reaction (VDRL 1.1%), HBsAg (3.9%), and hepatitis
C antibody (anti-HCV) (1.9%) was reported, with HBsAg
prevalence suggesting intermediate prevalence [[8]; see
additional file 1]. For the last three years in Afghanistan,
monovalent hepatitis B vaccine has been administered
simultaneously with diphtheria-pertussis-tetanus (DPT)
vaccine at two, four, and six months of life. In 2005, the
DPT completion rate for the Kabul urban area was esti-
mated to be 28.6% [9].
Hepatitis B virus (HBV) prevalence has also been reported
among Afghan refugee populations outside of Afghani-
stan, with higher prevalence noted than that reported
among Afghan blood donors [10,11]. Since 2002, the
return of 4.8 million refugees, largely from neighboring
countries with higher prevalence of HBV and hepatitis C
virus (HCV) (e.g. Iran, Pakistan), raises concern that prev-
alence of hepatitis and other blood-borne infections
within the country may increase [11]. Reliable general
population prevalence is also needed to inform evolving
vaccination and sexually transmitted infection (STI) pre-
vention programs. The purposes of this study were to
determine the prevalence and correlates of HIV, syphilis,
and hepatitis B and C infection and to model the impact
of various vaccination strategies at measured HBsAg prev-
alence among intrapartum patients in Kabul, Afghanistan.
Methods
Setting
Kabul, the capital of Afghanistan, had a population of
approximately 2.5 million in 2005, with an estimated
facility-based delivery rate for urban areas of 85.2%
[9,12]. There are four public maternity hospitals in the
city, providing free obstetric care locally and serving as
regional referral centers for other facility- or home-based
deliveries. At the time of the study, the three hospitals
with highest delivery volumes in the previous quarter
(Malalai, Rabia Balkhi, and Khair Khana) were included.
Prior to enrollment, approval was obtained from the
Afghan Ministry of Public Health and University of Cali-
fornia, San Diego (Protocol #060083) institutional review
boards. All study procedures were followed in accordance
with the ethical standards of these review boards.
Participants
Eligibility for this cross-sectional study was confined to
pregnant women admitted in stable medical condition;
women with conditions requiring urgent medical inter-
vention (e.g. eclampsia, hemorrhage), imminently deliv-
ering (cervical dilation ≥ 8 cm), or unable to provide
informed consent were excluded. Potential participants
were consecutively evaluated from June to September,
2006. Potential study participants either declining partic-
ipation or ineligible for participation were enumerated
and assessed by age or parity for comparison to enrolled
participants.
Questionnaire Development
Questionnaires were developed with input from a local
advisory board of reproductive health specialists in Kabul.
Following pilot-testing and board review, the final ques-
tionnaire was edited, translated, and back-translated for
accuracy. The instrument assessed demographics, socioe-
conomic status, and time spent outside the country,
including prior refugee status. Past medical and obstetric
history was queried, including number, site, year, and out-
come of prior deliveries and prenatal care for the current
pregnancy. Risk factors for sexually transmitted and
blood-borne infections, such as drug use or number of
therapeutic injections, were also assessed.Page 2 of 9
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Study representatives were female medical providers
(midwives and physicians) who were not employees of
the study hospitals. Study representatives were trained in
human subjects' research, questionnaire administration,
rapid testing, and pre and post-test counseling. Trained
representatives were present in shifts to ensure 24 hour
enrollment coverage. All women presenting for admission
were assessed for study entry. Following medical evalua-
tion and admission, eligible women were invited to
accompany the study representative to a private room for
informed consent; all women provided written informed
consent prior to enrollment. Consented participants were
assigned a study number, unlinked to any hospital identi-
fiers, that was the sole identifier on all study materials.
Participants completed an interviewer-administered ques-
tionnaire. Pre-test counseling, whole blood rapid testing
with finger stick specimen, and post-test counseling with
provision of results were then performed. Following these
activities, participants were escorted back to the labor
ward. Participants who were too uncomfortable for inter-
view or testing following consent were excused from the
study (n = 3); those who were somewhat uncomfortable
during interview had the interview suspended and testing
performed, with the questionnaire completed after deliv-
ery. Free testing was the only compensation provided for
participation.
Patient Testing and Prophylaxis
Rapid testing was performed with Abbott Determine® HIV
1/2, Syphilis TP, and HBsAg (Abbott Diagnostics Japan,
Tokyo, Japan) and with Standard Diagnostics Anti-HCV
(Standard Diagnostics Laboratories, Kyonggi-do, Korea).
A second rapid test (OraSure OraQuick HIV 1/2®, OraSure
Technologies, Bethlehem, PA) was available for tandem
HIV testing, with Western Blot (HIV BLOT 2.2®, GeneLabs
Diagnostics, Singapore) available for confirmation.
Treponema pallidum particle agglutination (TPPA) assay
(Fujirebio Diagnostics, Malvern, PA, USA) and rapid
plasma reagin (RPR) (Spectra Diagnostics, Cairo, Egypt)
were available for syphilis confirmation and clinical mon-
itoring. All participants with positive rapid tests under-
went intravenous sampling, from which serum was
prepared and stored for confirmatory testing.
HBV was confirmed with a second, serum-based rapid test
(Standard Diagnostics HBV, Standard Diagnostics Labora-
tories, Korea), as nucleic acid testing was not available.
Use of the Determine® and Standard Diagnostics® rapid
tests with sensitivities of 99.0% and 99.0% and specifici-
ties of 99.0% and 100.0%, respectively, have a positive
predictive value (PPV) of 99.988%, assuming a baseline
prevalence of HBsAg of 5.0% [13,14]. HCV antibody was
confirmed with RIBA (RIBA 3.0 SIA®, Chiron Corporation,
Emeryville, CA, USA). All confirmatory testing was per-
formed at the VCT Center in Kabul by trained laboratory
personnel.
Participants with any positive rapid test (or two for HIV)
were treated as presumptive positives and received intra-
or post-partum prophylaxis. Protocols were in place for
management of prevention of vertical transmission of
HIV or HBV and maternal and neonatal syphilis, follow-
ing international guidelines [15-17].
Analysis
Student's T-test and the binomial probability test were
used to compare participants and those ineligible or
declining entry. Descriptive statistics were generated to
further characterize the study population. Prevalence for
each infection was calculated with confidence intervals
based on the Poisson distribution for anti-HCV and
HBsAg. The sample size was sufficient to determine at
least a 28% difference in demographic and risk variables
between HBsAg-positive and HBsAg-negative participants
(P = 80%, two-sided alpha = 0.05). Correlates of HBsAg
were assessed with univariable logistic regression. Data
were entered and cleaned with EpiData 3.1 (EpiData Asso-
ciation, Odense, Denmark) and analyzed with Stata 8.0
(Stata Corp, College Station, Texas).
Hepatitis B vaccination modeling
The Hepatitis B Disease Burden and Vaccination Model
Version 1.2 from the Centers for Disease Control and Pre-
vention was used to estimate hepatitis cases averted for
several vaccination strategies, given measured HBsAg sero-
prevalence [18]. The model requires input of prevalence
of maternal hepatitis B e antigen (HBeAg) and child and
adult hepatitis B core antibody (anti-HBc) among those
positive for HBsAg, for which there is no data from Kabul.
A small study done among Afghan refugees in Iran
reported that, of women testing positive for HBsAg, no
women had HBeAg [11]. However, due to the small sam-
ple size, we elected to use data from other sources for this
calculation. India was the country of closest geographic
proximity with published HBeAg prevalence among ante-
natal populations positive for HBsAg, ranging between
7.8% and 18.0%; [19-21] we used the estimate of 12.5%
for presumed HBeAg prevalence among women testing
positive for HBsAg in the model. The model population
was the birth cohort for the maternity hospitals of Kabul
for 2006 less the probable neonatal and infant deaths
(based on national infant mortality rate, resultant n =
45,090). Estimates of anti-HBc of 30% for children and
60% for adults were used to complete the model, which
are identical to those used for a model created by the
World Health Organization in development of a HBV vac-
cination strategy for Afghanistan [22].Page 3 of 9
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Enrollment comprised 4,452 participants, with 1,179
women ineligible and 153 declining participation. Rea-
sons for ineligibility included imminent delivery
(62.9%), emergent operative intervention (22.5%), hem-
orrhage (7.2%), non-reassuring fetal status (6.7%), or
other reasons (e.g. eclampsia, 0.7%). Participants were
younger (mean 25.74 vs. 27.70, p < 0.001) and had lower
parity (mean 2.09 vs. 3.41, p < 0.001) than those ineligi-
ble. Women declining enrollment were of greater parity
(mean = 3.06, p < 0.001), but did not differ significantly
by age.
Demographic and healthcare access information is dis-
played in Table 1. Generally, participants were young,
originated from Kabul province, and had little or no for-
mal education. Regarding high risk behaviors, no partici-
pants reported personal non-medicinal drug use and only
2.0% (n = 90) reported drug use by their spouses, of
whom 45.5% stated that their husbands had ever injected
drugs. Few participants reported that their spouses had
Table 1: Descriptive Characteristics of Women Delivering in Government Hospitals between June and September, 2006 in Kabul, 
Afghanistan (n = 4452).
Variable Mean Median Range
Age 25.74 years 24 years 14 – 48 years
Age at Marriage 19.49 years 18 years 10 – 37 years
Number living in household 7.36 5 1 – 40
Variable Classification Number (%)
Ethnic Group (n = 4444) Tajik 3158 (71.1%)
Pashtun 339 (7.6%)
Hazara 923 (20.8%)
Other 24 (0.5%)
Country of Birth (n = 4448) Afghanistan 4420 (99.3%)
Other 28 (0.7%)
Province of Birth (n = 4422) Kabul & surrounding provinces 3492 (79.0%)
Northern 406 (9.2%)
Central 299 (6.8%)
Eastern 172 (3.9%)
Western 25 (0.6%)
Southern 28 (0.6%)
Lived outside Afghanistan in last 5 years (n = 4348): Yes 1650 (37.1%)
Educational Level (n = 4447) No formal education 2996 (67.4%)
1–2 years 179 (4.0%)
Finished primary school 404 (9.1%)
Some secondary school 326 (7.3%)
Finished secondary school 349 (7.9%)
Some university 113 (2.5%)
Finished university 80 (1.8%)
Frequency Family Eats Meat (n = 4447) < Once weekly 361 (8.1%)
Once weekly 1900 (42.7%)
Twice weekly 1492 (33.6%)
> Twice weekly 684 (15.6%)
Usual Means of Transport (n = 4444) Public Bus 1848 (41.6%)
Taxi 1366 (30.7%)
Family Car 1175 (26.4%)
On foot 39 (0.9%)
Motorcycle 9 (0.2%)
Horse cart 4 (0.1%)
Seen medical provider this pregnancy (n = 3930) Yes 3930 (88.4%)
Number of Prior Pregnancies 0 1495 (33.6%)
1 719 (16.2%)
2 653 (14.7%)
3 545 (12.2%)
4 364 (8.2%)
5 299 (6.7%)
≥ 6 377 (8.4%)
Last Birth Attended (n = 2936) Yes 2283 (77.3%)Page 4 of 9
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boys (0.2%, n = 7) or other women (0.7%, n = 30). Few
participants had lived in a refugee camp (6.5%, n = 289)
or had spouses that had been incarcerated (5.0%, n =
221). The majority had not received therapeutic injections
from either a medical (75.0%, n = 3,333) or non-medical
provider (99.1%, n = 4,405) in the last year.
No participants tested positive for either syphilis or HIV.
Prevalence of HBsAg was 1.53% (95% CI: 1.18 – 1.94)
and anti-HCV was 0.31% (95% CI: 0.17 – 0.53). There
were two false positive HBsAg Determine® rapid tests; the
second serum-based rapid test was negative (PPV =
97.1%). There were no participants testing positive for
both HBsAg and anti-HCV. The absence or low prevalence
of HIV, syphilis, and anti-HCV precluded subsequent
analysis of correlates.
Correlates of HBsAg
Only spousal educational level was associated with HBsAg
infection in univariate analysis (OR = 1.13, 95% CI: 1.01
– 1.26). When stratified by level of education, only those
women whose husbands had finished university were
more likely to have HBsAg, while women whose hus-
bands had no formal education were less likely to have
HBsAg (Table 2). There was no significant relationship
detected between a positive HBsAg test and any other var-
iable reflecting demographics, health care utilization, or
high-risk behaviors for either the participant or her spouse
in univariate analysis (data not shown).
Hepatitis B Vaccination Modeling
Based on measured prevalence of HBsAg, 1313 cases of
chronic HBV would be averted with current vaccination
practice (Table 3). Were birth dose vaccination introduced
with 85% coverage, perinatal cases would be reduced by
27% (Table 4). However, cases of chronic hepatitis, hepa-
tocellular carcinoma, or death from hepatic disease would
not be significantly altered with birth dose vaccination (p
= 0.11).
Discussion
This study is among the first to assess prevalence of HIV,
syphilis, HBV, and HCV in an obstetric population in
modern Afghanistan. HIV was not detected, corroborating
low prevalence noted in other Afghan populations [[8] –
see additional file 1;[23]]. Prevalence of both HBsAg and
HCV were lower than those detected through the Central
Blood Bank for Kabul province or among Afghan popula-
tions in refugee camps in Balochistan (i.e., the Northwest
Frontier province of Pakistan) or in southwest Iran [[8] –
see additional file 1; [10,11]]. The associations between
HBsAg and therapeutic injections or markers of low soci-
oeconomic status noted in among Afghan refugees and in
other settings were not detected in the study population,
perhaps because reported therapeutic injections in the last
year were fairly uncommon or because low prevalence
may have diminished the power to detect some associa-
tions [10,24,25]. Given the large number of Afghans
repatriating from areas of higher hepatitis prevalence in
the last five years, similar assessments should be consid-
ered in border areas where former refugee camp denizens
often initially reside upon repatriation.
It is unclear why the highest spousal educational level was
associated with hepatitis B. This relationship may reflect
husbands educated in countries with greater hepatitis B
prevalence who, following cessation of civil conflict,
returned to Afghanistan, married, and transmitted the
infection to their spouse. This relationship is similar to
that between HIV and higher educational level in rural
populations in Africa, where migration for education and
possibly infection occurred [26]. In the Afghan context,
adult hepatitis B transmission is likely to be iatrogenic or
sexual and may predominantly affect the male popula-
tion. A study assessing HBsAg seroprevalence among
blood donors in Pakistan noted males were more likely to
be infected than females; both this study and a study
exclusively looking at first-time male blood donors noted
that hepatitis B transmission likely occurred through
unclean medical or shaving supplies [27,28]. We did not
interview or test the spouses, but such an assessment may
be indicated.
Table 2: Stratified univariate logistic regression analysis of association between maternal hepatitis B surface antigen and husband's 
educational level (n = 4452).
Level of Husband's Education (n) Maternal HBsAg n, (%) OR, (95% CI)
No formal education (n = 1937) 20, (1.03%) 0.54, (0.32 – 0.91)
1 – 2 years of formal education (n = 97) 1, (1.03%) 0.67, (0.09 – 4.85)
Completed primary school (grade 6) (n = 400) 9, (2.25%) 1.56, (0.77 – 3.17)
Completed some secondary school (n = 505) 12, (2.38%) 1.69, (0.90 – 3.18)
Completed secondary school (n = 905) 15, (1.66%) 1.11, (0.62 – 1.98)
Completed some university (n = 225) 0, (0%) ------
Completed university or higher (n = 309) 11, (2.90%) 2.10, (1.09 – 4.05)Page 5 of 9
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BMC Infectious Diseases 2008, 8:119 http://www.biomedcentral.com/1471-2334/8/119Screening for HIV and syphilis has been posited as
optional in some low prevalence settings as resources
expended on screening are not justified by the low
number of infections detected [29]. However, analyses
indicate that screening for HIV and syphilis is cost effec-
tive even in very low prevalence settings [30,31]. We did
not detect any cases of HIV or syphilis among participants
delivering in government hospitals, suggesting that scarce
resources should not be diverted to screening at this time.
However, generalization of our findings is limited as only
women accessing care in government hospitals were
assessed.
In the case of hepatitis B, it is reasonable to consider peri-
partum testing with birth dose vaccine and parental coun-
seling to ensure completion of the vaccine series, as
reported rates of likely vaccination series completion are
sub-optimal [9]. Based on international recommenda-
tions on birth dose hepatitis B vaccination, modeling did
not suggest a significant advantage in changing the current
strategy [5,6,32]. However, due to the shifting population
dynamics in Afghanistan, routine surveillance should be
conducted as birth dose vaccination will be recom-
mended if antenatal prevalence of HBsAg reaches 2%
[5,33].
This study has a number of important limitations. First,
the population consists only of those women able to
access care, likely those of higher socioeconomic status.
Because hepatitis has been associated with lower socioe-
conomic status, the prevalence reported here may under-
estimate the true prevalence among reproductive-aged
women in Kabul. Second, there may have been under-
reporting of risky behaviors or other socially-desirable
responses in this interviewer-administered survey. Fur-
ther, as the questionnaire was administered during labor,
there may have been response truncation due to discom-
fort. We attempted to minimize this by conducting all
interviews in a private setting with a female interviewer.
However, interviewer administration was the only feasi-
ble means of data collection, due to low literacy and the
prohibitive cost of audio computer-assisted self-interview
Table 3: Hepatitis B acquisition and future burden estimates for infants born in government maternity hospitals with current 
vaccination programming with the DPT series in Kabul, Afghanistan.
Number Without Program Number With Program Number Prevented Percent Reduction
A. Disease Events Prevented (Future burden)
Total HBV infections 27,054 19,735 7,319 27%
Acute symptomatic hepatitis B cases 5,400 3,933 1,467 27%
Chronic HBV infections 4,937 3,625 1,313 27%
HBV-related deaths:
Acute hepatitis B 23 17 6 27%
Cirrhosis 268 197 71 27%
Hepatocellular carcinoma 170 125 45 27%
Total Deaths 460 338 123 27%
B. Number of Infections by Age at Acquisition of Infection (Future burden)
Perinatal Infection 117 117 0 0%
Early Childhood Infection 13,410 9,766 3,643 27%
Late Infection 13,527 9,852 3,675 27%
Total Infections 27,054 19,735 7,319 27%
C. Number of Chronic Infections by Age at Acquisition of Infection (Future burden)
Perinatal Infection 106 106 0 0%
Early Childhood Infection 4,021 2,929 1,093 27%
Late Infection 811 590 220 27%
Total Infections 4,937 3,625 1,313 27%
D. Number of Deaths by Age at Acquisition of Infection (Future burden)
Perinatal Infection 9 9 0 0%
Early Childhood Infection 362 264 98 27%
Late Infection 89 65 24 27%
Total Deaths 460 338 123 27%
Appendix. Input values
Prevalance HBsAg among women of child bearing age: 1.3
Prevalence HBeAg among HBsAg-positive women of child bearing age: 12.5
Prevalence of any marker of HBV infection among 5 year olds: 30
Prevalence of any marker of HBV infection among 30+ year olds: 60
Estimated Hepatitis B3 coverage: 28.6
Estimated coverage with birth dose hepatitis B vaccine: 0Page 6 of 9
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only with the participant's assent; if discomfort was pre-
venting response, the participant was offered the option
of resuming the questionnaire following delivery.
Conclusion
The findings of this study indicate that HIV and syphilis
were not present among intrapartum patients tested and
that HBsAg prevalence was lower than for other general
population groups assessed. A general screening program
for HIV and syphilis does not appear cost-effective when
the limited available resources are considered. However,
HBsAg prevalence indicates hepatitis B is a pertinent pub-
lic health issue and that routine surveillance among
antepartum populations should be considered, particu-
larly should HBeAg prevalence be assessed and found to
be high. Future programming should include viral hepati-
tis in public health service announcements and awareness
raising activities, potentially improving vaccination series
completion. Intrapartum screening with rapid testing is
feasible, acceptable, and suited for periodic surveillance
activities as population shifts may introduce measurable
changes in viral hepatitis prevalence, resulting in potential
change in vaccination policy and practice. However, other
models to disseminate testing, vaccine, and health infor-
mation should also be developed to reach populations
that do not access care centers and may be at greater risk
for these infections.
Abbreviations
ACASI: audio computer-assisted self-interview; Anti-HBc:
hepatitis B core antibody; DPT: diphtheria, pertussis, and
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Table 4: Hepatitis B acquisition and future burden estimates for infants born in government maternity hospitals with 85% birth dose 
hepatitis B vaccine coverage vaccination programming in Kabul, Afghanistan.
Number Without Program Number With Program Number Prevented Percent Reduction
A. Disease Events Prevented (Future burden)
Total HBV infections 27,054 19,708 7,346 27%
Acute symptomatic hepatitis B cases 5,400 3,933 1,467 27%
Chronic HBV infections 4,937 3,600 1,337 27%
HBV-related deaths:
Acute hepatitis B 23 17 6 27%
Cirrhosis 268 195 73 27%
Hepatocellular carcinoma 170 124 46 27%
Total Deaths 460 336 125 27%
B. Number of Infections by Age at Acquisition of Infection (Future burden)
Perinatal Infection 117 90 27 23%
Early Childhood Infection 13,410 9,766 3,643 27%
Late Infection 13,527 9,852 3,675 27%
Total Infections 27,054 19,708 7,346 27%
C. Number of Chronic Infections by Age at Acquisition of Infection (Future burden)
Perinatal Infection 106 81 24 23%
Early Childhood Infection 4,021 2,929 1,093 27%
Late Infection 811 590 220 27%
Total Infections 4,937 3,600 1,337 27%
D. Number of Deaths by Age at Acquisition of Infection (Future burden)
Perinatal Infection 9 7 2 23%
Early Childhood Infection 362 264 98 27%
Late Infection 89 65 24 27%
Total Deaths 460 336 125 27%
E. Number of HBV-Related Deaths in 2000 (Current burden)
Acute hepatitis B 166
Cirrhosis 1,130
Hepatocellular carcinoma 795
Total Deaths 2,090
Appendix. Input values
Prevalance HBsAg among women of child bearing age: 1.3
Prevalence HBeAg among HBsAg-positive women of child bearing age: 12.5
Prevalence of any marker of HBV infection among 5 year olds: 30
Prevalence of any marker of HBV infection among 30+ year olds: 60
Estimated Hepatitis B3 coverage: 28.6
Estimated coverage with birth dose hepatitis B vaccine: 85%Page 7 of 9
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